SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001387131-20-008322
Filing Date
2020-09-15
Accepted
2020-09-15 16:21:37
Documents
14
Period of Report
2020-09-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT admp-8k_091420.htm   iXBRL 8-K 28291
2 AUGUST 2020 AMENDMENT TO LOAN AMENDMENT AND ASSUMPTION AGREEMENT ex10-1.htm EX-10.1 29516
3 AMENDED PROMISSORY NOTE ex10-2.htm EX-10.2 35085
  Complete submission text file 0001387131-20-008322.txt   285467

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT admp-20200914.xsd EX-101.SCH 3225
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT admp-20200914_lab.xml EX-101.LAB 34591
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT admp-20200914_pre.xml EX-101.PRE 22736
7 EXTRACTED XBRL INSTANCE DOCUMENT admp-8k_091420_htm.xml XML 3595
Mailing Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130 (858) 997-2400
Adamis Pharmaceuticals Corp (Filer) CIK: 0000887247 (see all company filings)

IRS No.: 820429727 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36242 | Film No.: 201176223
SIC: 2834 Pharmaceutical Preparations